Global Immuno-oncology Drugs Market

By Author: Rupali Dagade
Total Articles: 446
Comment this article

Global Immuno-oncology Drugs Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 12.4% during the forecast period.
Global Immuno-oncology Drugs Market Overview:

Immuno-oncology is the artificial stimulation of the immune system to treat cancer, improving the immune system's ability to fight the disease. This needs to be personalized because anticancer immune responses can be inhibited in several ways that vary from patient to patient.
Global Immuno-oncology Drugs Market Dynamics:

Technological developments are expected to boost the Immuno-oncology drugs market.

Immuno-oncology is considered to be a promising therapy in treating cancer owing to the recent developments in drug discovery and development. The growing number of Immuno-oncology treatments, which are in different phases of clinical trials, and the increasing approval of Immuno-oncology therapies by the FDA are leading to the acceptance of new and advanced technologies in the field of Immuno-oncology therapy. These factors help in propelling the market growth.

The increasing prevalence of cancer patients ...
... globally serves to be the primary growth factor for the Immuno-oncology drugs market. The rising adoption of immunotherapies over the traditional chemotherapies, increase in popularity of advanced therapies (biological and targeted drug therapies), and surge in the geriatric population worldwide are the key factors driving the growth of the market. According to the WHO, cancer is the second leading cause of death worldwide and an estimated 9.6 million deaths in 2018.

The approval of therapeutic solutions in the Immuno-Oncology segment is poised to rapidly increase due to the growing recognition of durable tumour responses. Hence, the competition between pharmaceutical players is intensifying as they strive to achieve first-mover advantages in specific medical applications. However, the high cost involved in new drug development and the threat of failure & adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market.

The report has profiled eighteen key players in the market from different regions. However, the report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for a future hot spot in APAC region.
Global Immuno-oncology Drugs Market Segment Analysis:

The Global Immuno-oncology Drugs Market is segmented on the basis of Drug Type, Application and End-Users.

Based on Drug Type, the immune checkpoint inhibitors segment is expected to hold a dominant market share and along with this, the CAR T cell therapy segment is expected to witness lucrative growth during the forecast period. The immune checkpoint inhibitors have had remarkable success across multiple malignancies, and are the most well-established therapeutic class of Immuno-oncology agents to date.

The immune checkpoint inhibitor, ipilimumab, which is considered a game-changer in cancer treatment received its FDA approval in 2011. Currently, 11 immune checkpoint inhibitors (Table 1) and 2 chimeric antigen receptor T cell (CAR-T) products have been approved in treating 16 types of malignant diseases and 1 tissue-agnostic indication. These drugs target cell surface checkpoint proteins to stimulate the recognition and destruction of cancer cells by the immune system.

The CAR T Cell Therapy segment is expected to witness lucrative growth during the forecast period. The rising prevalence of cancer and demand for effective treatment is considered to be the major drivers for the segment growth. In May 2020, researchers from University Hospital Heidelberg, Germany, reported that sufficient yield of lymphocytes for CAR-T cell production is feasible also for patients with low peripheral blood counts.

Global Immuno-oncology Drugs Market

To know about the Research Methodology :- Request Free Sample Report
Global Immuno-oncology Drugs Market Regional Insights:

Global Immuno-oncology Drugs Market Regional Insights

North America is expected to hold a larger market share, followed by Europe during forecast years.

The Region is experiencing exponential growth over the last 5 years. It accounted for a market share of 67.1% in 2016 and is experiencing a continuous increase since then. The commercial success is attributed to multiple factors, including speed-to-market, clinical & commercial positioning, marketing approach, and patient group targeting.

In recent times, pharma companies are turning to Immuno-Oncology to address some of the most pressing challenges in curing cancer. Various national and international conferences are being arranged such as the Clinical Immuno-Oncology Symposium in Orlando, Florida, organized by ASCO and SITC (Society for Immunotherapy and Cancer), where Scientists, pharma companies, and global healthcare organizations are exchanging research results.

Asia Pacific is expected as the fastest-growing region during the forecast period at a CAGR of xx%.

The Asia Pacific will command the global market owing to the drivers like improved medical infrastructure, increased patient awareness and rise in disposable income. Cancers with high somatic mutations such as melanoma, lung, bladder, stomach or oesophageal cancer are known to be more responsive to immunotherapies. These cancers are highly prevalent in the Asia-Pacific region.

Over 600 sites across Asia-Pacific have been involved in the clinical development of now approved IO drugs, and hundreds more are experienced in managing clinical trials with immunotherapies. Many sites across Asia-Pacific have developed a strong track record in managing clinical trials with immunotherapies. Countries such as China, Australia and South Korea are the main locations for these trials with 205, 189 and 76 sites respectively that have been involved in trials for FDA approved Immunotherapies. The market is anticipated to experience fast development in demand for Immuno-oncology drugs in emerging countries such as China, India and South Korea over the forecast period.

The report also helps in understanding the Global Immuno-oncology Drugs Market dynamics, structure by analyzing the market segments and project the Global Immuno-oncology Drugs Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Immuno-oncology Drugs Market make the report investor’s guide.
Global Immuno-oncology Drugs Market Key developments:

• In June 2020, Targovax, a Norway based biotechnology company, collaborated with the Explorations in Global Health (ExGloH) division of Leidos for evaluating the potential of using ONCOS, a Targovax's clinical program of oncolytic adenoviruses as a vector to encode MicrotideT checkpoint inhibitor peptides.
Competitive Landscape:

• Bristol-Myers Squibb’s immuno-oncology portfolio is the prime driver of the company’s growth since 2016. Its immuno-oncology drug Opdivo has been approved by FDA for more than ten cancer indications. Regulatory authorities confidently state about Opdivo’s clinical profile to rapidly uptake the global market in a short time span.

In 2016, BMS achieved multiple milestones in Opdivo research programs. Altogether, 15 registrational trials were concluded with positive results. Although BMS’s optimistic predictions are reasonably established, the drug is expected to see increased competition from Merck’s Keytruda.

• Merck & Co. recorded sales worth USD 1.4 billion in 2016 for their immuno-oncology drug Keytruda. That’s a 148% year-on-year growth as compared to USD566 million in 2015. To highlight its growing success, Keytruda accounted for USD 483 million global sales in the 4th quarter of 2016. The US market accounted for about 65% of the total Keytruda’s sales. Further strengthening their position, Merck & Co. has acquired IOmet, the UK-based drug discovery company focused on cancer metabolism and innovative medicinal drugs for treating cancer. Merck & Co. acquired its comprehensive pre-clinical pipelines

For more information visit@ https://www.maximizemarketresearch.com/market-report/global-immuno-oncology-drugs-market/98268/

Global Immuno-oncology Drugs Market Scope: Inquire before buying

Global Immuno-oncology Drugs Market
Global Immuno-oncology Drugs Market, by Region:

• North America
• Europe
• South America
• MEA
• APAC
Global Immuno-oncology Drugs Market Key players:

• Amgen, Inc.
• Astrazeneca Plc
• Bristol-Myers Squibb
• Celgene Corporation
• Eli lilly and Company
• Sanofi
• F. Hoffmann-La Roche
• Novartis AG
• Abbvie, Inc.
• Pfizer Inc.
• Johnson & Johnson
• Agenus Inc.
• Enzo Biochem, Inc.
• Lonza Group
• Bio-Rad Laboratories, Inc.
• Avantor, Inc.
• Spring Bank Pharmaceuticals, Inc.
• Ferring Pharmaceuticals

This report submitted by Maximize market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk,Pune, Maharashtra 411051, India.

Contact: +919607195908